XML 26 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Net Revenue $ 86,672,425 $ 64,989,842
Cost of goods sold 8,139,901 7,852,686
Gross profit 78,532,524 57,137,156
Operating expenses    
Selling, general and administrative 76,559,863 56,994,753
Research and development 5,703,362 4,132,425
Depreciation and amortization [1] 4,923,224 3,675,026
Change in fair value of earnout liabilities (1,938,451) (3,449,895)
Total operating expenses 85,247,998 61,352,309
Operating loss (6,715,474) (4,215,153)
Other income (expense)    
Interest expense (3,128,395) (475,783)
Share of losses from equity method investments (90,007)
Interest income 21,978
Gain on disposal of investment 251,034
Total other income (expense) (3,196,424) (224,749)
Net loss (9,911,898) (4,439,902)
Less: Net loss attributable to noncontrolling interest (247,351) (136,705)
Net loss attributable to Sanara MedTech shareholders $ (9,664,547) $ (4,303,197)
Net loss per share of common stock, basic $ (1.14) $ (0.52)
Net loss per share of common stock, diluted $ (1.14) $ (0.52)
Weighted average number of common shares outstanding, basic 8,484,224 8,278,949
Weighted average number of common shares outstanding, diluted 8,484,224 8,278,949
[1] Includes a $506,836 non-cash charge during the fourth quarter of 2024 to write-off the remaining net book value of certain THP internal use software assets.